Cerevel Therapeutics Holdings, Inc. Cerevel Therapeutics Holdings, Inc.

Cerevel Therapeutics Holdings, Inc.

CERE

株式のランク #2798
Cerevel Therapeutics Holdings, Inc. is a clinical-stage biopharmaceutical firm... Cerevel Therapeutics Holdings, Inc. is a clinical-stage biopharmaceutical firm dedicated to developing treatments for a range of neuroscience disorders. The company boasts a robust pipeline of therapeutic candidates currently undergoing various phases of clinical evaluation. Key assets include emraclidine, a positive allosteric modulator (PAM) in Phase 1b trials for schizophrenia. Another PAM, Darigabat, is being assessed in a Phase 2 proof-of-concept study for drug-resistant focal onset seizures in epilepsy, as well as in a Phase 1 trial for acute anxiety. For Parkinson's disease, Cerevel is advancing Tavapadon, a selective dopamine D1/D5 partial agonist, through Phase 3 clinical trials for both early and late stages of the condition. A related compound, CVL-871, also a selective dopamine D1/D5 partial agonist, is in Phase 2a trials for dementia-related apathy. The company's portfolio further includes CVL-936, a selective dopamine D3-preferring antagonist in Phase I for substance use disorder; CVL-354, a selective kappa-opioid receptor antagonist targeting major depressive disorder and substance use disorder; and CVL-047, a selective PDE4 inhibitor also aimed at major depressive disorder and substance use disorder. Beyond individual compounds, Cerevel is actively developing an M4 agonist program for psychosis and related indications, alongside an LRRK2 inhibitor program designed to address the progression of Parkinson's disease. Founded in 2018, Cerevel Therapeutics is headquartered in Cambridge, Massachusetts.
株価
$44.96
最終同期: 2024-08-01
時価総額
$6.67B
変化(1日)
0.00%
変化(1年)
0.00%
国
US
取引 Cerevel Therapeutics Holdings, Inc. (CERE)

カテゴリー

Healthcare
Cerevel Therapeutics Holdings, Inc.(CERE)の配当履歴
Cerevel Therapeutics Holdings, Inc.(証券コード:CERE)は合計で0回の配当を行いました。
すべての配当の合計(株式分割調整済み)は:0.00
配当利回り(TTM):0
2026から2026までのCerevel Therapeutics Holdings, Inc.(CERE)の配当履歴
年間配当支払い
年 配当(株式分割調整済み) 変化
提供された日付のデータは十分ではありません。
すべての配当支払いの一覧
年 配当 変化
提供された日付のデータは十分ではありません。
同業他社や競合企業の配当履歴
企業 配当支払い回数 国
0.00%
US
0.00%
US
64.00%
AU
0.00%
CH
0.00%
NL